Research Paper

TBX20 loss-of-function mutation responsible for familial tetralogy of Fallot or sporadic persistent truncus arteriosus

Ri-Tai Huang1*, Juan Wang2*, Song Xue3, Xing-Biao Qiu3, Hong-Yu Shi3, Ruo-Gu Li3, Xin-Kai Qu3, Xiao-Xiao Yang3, Hua Liu3, Ning Li3, Yan-Jie Li3, Ying-Jia Xu3, Yi-Qing Yang3,4,5,6

1. Department of Cardiovascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Road, Shanghai 200127, China; 2. Department of Cardiovascular Medicine, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai 200120, China; 3. Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Road, Shanghai 200030, China; 4. Department of Cardiovascular Research Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Road, Shanghai 200030, China; 5. Department of Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Road, Shanghai 200030, China.

* These two authors contributed equally to this work.

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2016.10.06; Accepted: 2016.12.20; Published: 2017.03.11

Abstract

Congenital heart disease (CHD), the most common form of developmental abnormality in humans, remains a leading cause of morbidity and mortality in neonates. Genetic defects have been recognized as the predominant causes of CHD. Nevertheless, CHD is of substantial genetic heterogeneity and the genetic defects underlying CHD in most cases remain unclear. In the current study, the coding regions and splicing junction sites of the TBX20 gene, which encodes a T-box transcription factor key to cardiovascular morphogenesis, were sequenced in 175 unrelated patients with CHD, and a novel heterozygous TBX20 mutation, p.K274X, was identified in an index patient with tetralogy of Fallot (TOF). Genetic analysis of the proband’s available family members showed that his father, elder brother and son had also TOF. In addition, his father and elder brother had also atrial septal defect, and his niece had persistent truncus arteriosus and ventricular septal defect. Analysis of the pedigree revealed that the mutation co-segregated with CHD transmitted in an autosomal dominant fashion, with complete penetrance. The nonsense mutation, which was absent in the 800 control chromosomes, was predicted to produce a truncated protein with only the amino terminus and partial T-box domain left. Functional analyses by using a dual-luciferase reporter assay system showed that the mutant TBX20 lost the ability to transactivate the target gene ANF. Furthermore, the mutation reduced the synergistic activation between TBX20 and NKX2.5 as well as GATA4, two other transcriptional factors previously associated with various CHD, encompassing TOF. This study firstly links TBX20 loss-of-function mutation to familial TOF or sporadic persistent truncus arteriosus, providing novel insight into the molecular pathogenesis of CHD.

Key words: Congenital heart disease; Tetralogy of Fallot; Genetics; Transcriptional factor; TBX20; Reporter gene assay

Introduction

Congenital heart disease (CHD), which defines a large set of structural defects of the heart and intra-thoracic great vessels that occur during embryogenesis, is the most prevalent form of human birth defect worldwide, affecting approximately 1% of live births, with an estimated prenatal incidence of
transcription factors, TBX20 have been shown to play a key and dose-sensitive role in cardiovascular genesis. In humans and vertebrate models, TBX20 is abundantly expressed in the heart throughout cardiac development [50]. In mice, TBX20 is abundantly expressed in the heart progenitor cells, cardiomyocytes of the early heart tube and endothelial cells responsible for endocardial cushions, as well as the precursor structures required for the development of cardiac valves and atroventricular septum [51]. Targeted disruption of murine Tbx20 led to embryonic death, with unlooped and severely hypoplastic myocardial tubes; while heterozygous Tbx20-null mice suffered from atrial septal anomalies [52–54]. By contrast, Tbx20-knockdown mice exhibited failed septation of the outflow tract, persistent truncus arteriosus and hypoplastic right ventricle [55]. Additionally, in zebrafish and Xenopus, either loss- or gain-of-function of Tbx20 resulted in cardiac development abnormalities [52]. In humans, mutations in TBX20 have been associated with atrial septal defect, ventricular septal defect, TOF and double-outlet right ventricle [30,31,56–60]. These findings make it justifiable to screen TBX20 as a prime candidate gene for CHD in another cohort of patients with CHD.

Materials and methods

Ethics

This study was performed in accordance with the ethical principles of the Declaration of Helsinki. The study protocol was reviewed and approved by the local institutional ethics committee, and written informed consents to the use of the blood samples for genetic analyses were obtained from the study participants or their guardians prior to commencement of this investigation.

Study population

In this study, a cohort of 175 unrelated patients, who fulfilled the criteria of CHD, was recruited from the Han Chinese population. The available family members of the index patient carrying an identified TBX20 mutation were also included. A total of 400 unrelated non-CHD individuals from the same geographic area, who were matched to the CHD cases in age, gender and ethnicity, were registered as control subjects. All the study participants were clinically evaluated in detail, including comprehensive individual and medical histories, detailed physical examination, standard 12-lead electrocardiogram, and transthoracic echocardiography with color flow Doppler. Transesophageal echocardiography, cardiac catheter-based procedure or surgery was performed only when there was a strong clinical indication.
Various forms of CHD were diagnosed by cardiac ultrasonic imaging and medical records. The patients who were diagnosed with chromosomal abnormalities or syndromic CHD, such as trisomy 13, trisomy 18, trisomy 21, Turner syndrome, Alagille syndrome, Holt-Oram Syndrome and Noonan syndrome, were excluded from the current study. Clinical research was conducted by professionals without knowledge of genotype.

**Mutational analysis of TBX20**

Peripheral venous blood samples were drawn from all study subjects. Genomic DNA was isolated from whole blood leukocytes using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA) according to the manufacture’s protocol. The primers to amplify the complete exonic sequences as well as small flanking intronic sequences of TBX20 by polymerase chain reaction (PCR) were designed as described previously [30], and was synthesized commercially (Sangon, Shanghai, China). The total volume of a PCR mixture was 25 μL, comprising 11.25 μL of deionized water, 5 μL of 5x Q solution, 2.5 μL of 10x buffer, 2 μL of dNTPs (2.5 mM each), 1 μL of each primer at 20 μM, 0.25 μL of HotStar Taq DNA Polymerase (Qiagen, Hilden, Germany) at 5 U/μL, and 2 μL of genomic DNA at 200 ng/μL. Typical PCR cycling parameters were pre-denaturation of template and activation of polymerase at 95 °C for 15 minutes, followed by 35 cycles of denaturation at 94 °C for 30 seconds, annealing at 62 °C for 30 seconds and extension at 72 °C for 1 minute, with a final extension at 72 °C for 10 minutes. Amplification of genomic DNA was performed in 0.2 ml thin-walled PCR tubes on a GeneAmp PCR System 9700 (Applied Biosystems, Foster, CA, USA). The amplified products were fractionated by electrophoresis on 1.5% agarose gels. After purification with the QIAquick Gel Extraction Kit (Qiagen), both strands of each amplicon were PCR-sequenced with the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) on an ABI PRISM 3130 XL automated DNA analyzer (Applied Biosystems). Resultant sequences were analyzed with a sequence analysis software (Applied Biosystems) and the BLAST program (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Whenever a sequence variant was found, the sample was PCR-sequenced again from both forward and reverse directions to confirm the nucleotide change. For a confirmed mutation, its position was based on the complementary DNA reference sequence for TBX20 (accession no. NM_001077653.2), with the initial codon ATG numbered as residue 1. Additionally, the online databases for human sequence variations, such as the single nucleotide polymorphism (SNP; http://www.ncbi.nlm.nih.gov/SNP) database and the human gene mutation (HGM; http://www.hgmd.org) database, were queried to confirm its novelty.

**Alignment of multiple TBX20 protein sequences across species**

The amino acid sequences of the TBX20 proteins in human, chimpanzee, monkey, dog, cattle, mouse, fowl, zebrafish and frog were obtained from the GenBank database (http://www.ncbi.nlm.nih.gov/genbank/). By using the Clustal Omega software (http://www.clustal.org/omega/), multiple alignments of amino acid sequences among these species were performed.

**Plasmid constructs and site-directed mutagenesis**

The recombinant expression vector TBX20-pcDNA3.1, which contains the full-length cDNA of human TBX20, was constructed as previously described [30]. The expression plasmids NKX2.5-pEFSA and GATA4-pSSRa as well as the atrial natriuretic factor-luciferase (ANF-luc) reporter construct, which contains the 2600-bp 5’-flanking region of the ANF gene and encodes the Firefly luciferase, were generously provided by Dr. Ichiro Shiojima, at the Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. With a complementary pair of primers, the identified mutation was introduced into the wild-type TBX20-pcDNA3.1 construct by PCR-based site-directed mutagenesis using the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The mutant underwent selection by DpnI (TaKaRa, Dalian, China) and was fully sequenced to verify the desired mutation and to exclude any other unwanted sequence variations.

**Reporter gene assay of mutant TBX20**

Chinese hamster ovary (CHO) cells and COS-7 (a fibroblast-like cell line) cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum at 37°C in an incubator supplied with 5% CO2 and maintained in 12-well plates under standard conditions for 48 hours after transfection. One day before transfection, cells were plated at a density of 2×104 cells/well. The PolyFect Transfection Reagent (Qiagen) was used for transfection of cells according to the manufacturer’s instructions. The internal control reporter plasmid pGL4.75 (hRLuc/CMV, Promega), which expresses Renilla luciferase, was used in transient transfection...
assays to normalize the transfection efficiency. Twenty-four hours after plating, CHO cells grown to approximately 90% confluence were transfected with 0.8 μg of wild-type or mutant TBX20-pcDNA3.1 expression vector, 1.0 μg of ANF-luc reporter construct, and 0.04 μg of pGL4.75 control reporter vector. For co-transfection experiments in CHO cells, 0.4 μg of wild-type TBX20-pcDNA3.1 together with 0.4 μg of empty pcDNA3.1 vector were used in the presence of 1.0 μg of ANF-luc and 0.04 μg of pGL4.75. For the synergistic activation between TBX20 and NKX2.5 or GATA4 in COS-7 cells, the same amount (0.6 μg) of plasmid (empty pcDNA3.1, wild-type TBX20-pcDNA3.1, NKX2.5-pEFSA, GATA4-pSSRa or K274X-mutant TBX20-pcDNA3.1) was used alone or together, in combination with 1.0 μg of ANF-luc and 0.04 μg of pGL4.75. Transfected cells were washed once on the following day with medium before being refreshed with new medium. Forty-eight hours after transfection, cells were harvested and lysed, and then the Firefly luciferase and Renilla luciferase activities were measured with the Dual-Glo Luciferase Assay Kit (Promega) according to the manufacturer’s instructions. For promoter activity assays, all experiments were performed at minimum in triplicate and data are reported as the ratio of Firefly luciferase to Renilla luciferase.

Statistical analysis

All statistical analyses were carried out with the SPSS for Windows software version 19.0 (SPSS, Chicago, IL, USA). Quantitative data are expressed as means ± standard deviations (SD). Student’s unpaired t test was used to compare quantitative variables between two groups. Comparison of the qualitative variables between two groups was made by using Pearson’s χ² test or Fisher’s exact test when appropriate. All reported p values were two-tailed and statistical significance was defined as p < 0.05.

Results

Clinical findings

A cohort of 175 unrelated patients with CHD underwent a comprehensive clinical evaluation in contrast to a total of 400 unrelated non-CHD control individuals. All the studied patients had echocardiographically or surgically confirmed CHD; while the control subjects had no evidence of congenital defects in cardiovascular structures or positive family history of CHD. None of the study participants had recognized environmental risk factors for CHD, such as maternal viral infection, drug use and long-term exposure to toxic chemicals or ionizing radiation in the first trimester of pregnancy. There is no significant difference in age, gender or ethnicity between patient and control groups. The demographic profiles and clinical features of the CHD patients are summarized in Table 1.

| Variables                              | Statistics           |
|----------------------------------------|----------------------|
| Male gender (%)                        | 98 (56)              |
| Female gender (%)                      | 77 (44)              |
| Age (years)                            | 4.3 ± 3.1            |
| Positive family history of congenital heart disease (%) | 42 (24)              |
| Clinical classification of congenital heart disease (%) | 34 (19)              |
| Isolated congenital heart disease (%)  | 75 (43)              |
| Ventricular septal defect (%)          | 26 (15)              |
| Atrial septal defect (%)               | 23 (13)              |
| Patent ductus arteriosus (%)           | 9 (5)                |
| Double outlet of right ventricle (%)   | 5 (3)                |
| Abnormal pulmonary venous connection (%) | 4 (2)            |
| Truncus arteriosus (%)                 | 3 (2)                |
| Endocardial cushion defect (%)         | 2 (1)                |
| Hypoplastic left ventricle (%)         | 2 (1)                |
| Hypoplastic right ventricle (%)        | 1 (1)                |
| Complex congenital heart disease (%)   | 100 (57)             |
| Tetralogy of Fallot (%)                | 49 (28)              |
| Atrial septal defect + ventricular septal defect (%) | 12 (7)              |
| Ventricular septal defect + patent duc tus arteriosus (%) | 8 (5)                |
| Atrial septal defect + tetralogy of Fallot (%) | 7 (4)               |
| Atrial septal defect + patent duc tus arteriosus (%) | 7 (4)                |
| Double outlet of right ventricle + ventricular septal defect (%) | 6 (3)                |
| Ventricular septal defect + transposition of the great arteries (%) | 6 (3)                |
| Ventricular septal defect + truncus arteriosus (%) | 5 (3)                |
| Incidence of arrhythmias               | 16 (9)               |
| Atrioventricular block (%)             | 10 (6)               |
| Atrial fibrillation (%)                | 6 (3)                |
| Treatment of congenital heart disease  |                     |
| Surgical repair (%)                    | 121 (69)             |
| Catheter-based closure (%)             | 43 (25)              |
| Follow-up (%)                          | 11 (6)               |

Data are expressed as means and standard deviations, number or percentage.

Identification of a novel TBX20 mutation

By sequence analysis of the TBX20 gene in 175 unrelated patients with CHD, a novel sequence variation was identified in a patient with TOF, who had a positive family history of CHD. Specifically, a substitution of thymine for adenine in the first nucleotide of codon 274 (c.820A>T), which was predicted to produce a premature stop codon at amino acid position 274 (p.K274X), was identified in the index patient from family A. The sequence chromatograms showing the detected heterozygous TBX20 mutation and its homozygous control sequence are presented in Figure 1A. The schematic diagrams showing the full-length and truncated TBX20 proteins were displayed in Figure 1B. The nonsense mutation was absent in the 800 control chromosomes and not found in the SNP and HGM databases (accessed again October 3, 2016). Genetic analysis of the proband’s available family members
showed that his father (I-1), elder brother (II-1) and son (III-3) had also TOF. In addition, his father (I-1) and elder brother (II-1) had also congenital atrial septal defect, presenting with pentalogy of Fallot, and his niece (III-2) had persistent truncus arteriosus and ventricular septal defect. Analysis of the pedigree revealed that the mutation co-segregated with CHD transmitted in an autosomal dominant fashion, with complete penetrance (Figure 1C). The phenotypic characteristics and status of TBX20 mutation of the affected family members are reported in Table 2.

Evolutionary conservation
As shown in Figure 2, human TBX20 was aligned with orthologous proteins from multiple species, exhibiting that the altered lysine at amino acid position 274 was highly conserved evolutionarily.

| Individual | Gender | Age (years) | Cardiac structural defects | TBX20 mutation |
|------------|--------|-------------|----------------------------|----------------|
| Family A   |        |             |                            | K274X          |
| I-1        | M      | 53          | TOF, ASD                   | NA             |
| II-1       | M      | 31          | TOF, ASD                   | */–            |
| III-2      | F      | 0           | PTA, VSD                   | */–            |
| III-3      | F      | 2           | TOF                        | */–            |

M, Male; F, female; TOF, tetralogy of Fallot; ASD, atrial septal defect; PTA, persistent truncus arteriosus; VSD, ventricular septal defect; NA, not available; */–, heterozygote.

a Age at death.
symbol with a slash, deceased member; closed symbol, affected member; open symbol, unaffected member; arrow, proband; +, carrier of the heterozygous mutation; −, non-carrier.

Figure 2. Alignment of multiple TBX20 protein sequences across species. The altered lysine at amino acid position 274 (p.K274) of TBX20 is highly conserved evolutionarily among multiple species.

**Functional defects of mutant TBX20 in transcriptional activation**

As shown in Figure 3, the same amount (0.8 μg) of wild-type TBX20 and K274X-mutant TBX20 (K274X) activated the ANF promoter by ~11-fold and ~1-fold, respectively. When wild-type TBX20 (0.4 μg) was co-expressed with the same amount (0.4 μg) of K274-mutant TBX20 or empty pcDNA3.1 plasmid, the induced activation of the ANF promoter was ~6-fold or ~7-fold. These results indicate that the K274-mutant TBX20 has no transcriptional activity or significantly dominant-negative effect on its wild-type counterpart.

Figure 3. Failure of the mutant TBX20 to transactivate a target gene. Activation of the ANF-luciferase reporter in cultured CHO cells by wild-type TBX20 or K274X-mutant TBX20 (K274X), alone or together, showed that the K274X-mutant TBX20 had no transcriptional activity or significantly inhibitory effect on its wild-type counterpart. Experiments were carried out in triplicate and data were expressed as mean and standard deviations. * indicates \( t = 5.7200, p = 0.0046 \), and ** indicates \( t = 13.5396, p = 0.0002 \), when compared with wild-type TBX20 (0.8 μg).

**Reduced synergistic activation between TBX20 and NKX2.5 as well as GATA4 by the mutation**

As shown in Figure 4, in the presence of NKX2.5, the same amount (0.6 μg) of wild-type TBX20 and K274X-mutant TBX20 (K274X) activated the ANF promoter by ~16-fold and ~9-fold, respectively; while in the presence of GATA4, the same amount (0.6 μg) of wild-type TBX20 and K274X-mutant TBX20 (K274X) activated the ANF promoter by ~25-fold and ~4-fold, respectively. These data indicate that the mutation diminishes the synergistic activation between TBX20 and NKX2.5 as well as GATA4.

**Discussion**

In this study, by sequence analysis of the TBX20 gene, a novel heterozygous mutation, c.820A>T, which was predicted to generate a truncated protein (p.K274X), was discovered in a family with CHD, including familial TOF and atrial septal defect as well as sporadic persistent truncus arteriosus and ventricular septal defect. In the family, the mutation co-segregated with CHD with complete penetrance. The nonsense mutation was absent in the 800 referral chromosomes from a control population matched in ethnicity and gender. A cross-species alignment of TBX20 proteins showed that the affected amino acid was highly conserved evolutionarily. Biochemical analyses demonstrated that the mutant TBX20 failed to transactivate a target gene. Furthermore, the mutation reduced the synergistic activation between TBX20 and NKX2.5 as well as between TBX20 and GATA4.
Therefore, it is probable that functional failure of TBX20 confers an enhanced susceptibility to CHD in these mutation carriers.

TBX genes encode a large family of transcription factors that are characterized by a highly conserved DNA-binding motif of 180 amino acid residues, T-box. This T-box recognizes a specific DNA element, the T-half site (the consensus DNA sequence of 5-AGGTGTGA-3), that exists singly, or in multiples with different orientation and spacing in the promoters of target genes, and regulates transcriptional activation or inhibition. Moreover, the T-box is also a conserved interaction domain for other transcription factors, chromatin remodelling complexes and histone-modifying enzymes involved in transcriptional mediation [50]. In this study, the identified mutation is predicted to yield a truncated protein (p.K274X), losing partial T-box along with the carboxyl terminus, thus may be anticipated to impair the transcriptional function of TBX20 probably by interfering with the specific binding to target genes or the interaction with partners of TBX20.

TBX20 has been demonstrated to transactivate multiple target genes that are expressed in the heart during embryogenesis, including ANF, CX40 and CX45, of which ANF is the most extensively investigated one, and its expression in the embryonic heart has been established by synergistic action of TBX20, NKX2.5, GATA4 and other transcriptional factors [50,51]. In this study, the functional roles of a novel TBX20 mutation identified in familial TOF patients were evaluated by transcriptional activity assays, and the results revealed no transcriptional activation of the ANF promoter by the mutant TBX20 protein, alone or together with NKX2.5 or GATA4. These functional data indicate that haploinsufficiency of TBX20 is potentially an alternative molecular mechanism underpinning TOF.

Previous studies have validated that TBX20 physically interacts with multiple transcription factors, including homeobox transcription factor NKX2.5 and zinc-finger transcription factors GATA4, GATA5 and GATA6, cooperating to synergistically activate the expression of several target genes key to cardiogenesis [50,51], and loss-of-function mutations in such transcriptionally cooperative partners as NKX2.5, GATA4, GATA5 and GATA6 have been associated with a wide spectrum of CHD, including atrial septal defect, ventricular septal defect and TOF [34,36,37,50–52,56], which suggest that genetically compromised TBX20 contributes to CHD probably by diminishing synergistic activation of cardiac core genes with these cooperative partners.

Previously, TBX20 mutations have been associated with CHD. In fact, so far at least 13 mutations in the coding region of TBX20 have been identified to be responsible for a great variety of CHD. Kirk et al. [56] sequenced the whole coding exons of TBX20 in 353 index patients with CHD, and identified two heterozygous mutations (p.I152M and p.Q195X) in two index patients with familial CHD. Specifically, in family 1 harboring the missense mutation p.I152M, the proband had atrial septal defect; her grandmother had ventricular septal defect, and her mother had patent foramen ovale. In family 2 carrying the nonsense mutation p.Q195X, the proband had atrial septal defect and coarctation of the aorta, and his mother had mitral valve prolapse with mild regurgitation, dilated cardiomyopathy, and apicalateral hypertrophy. Functional deciphers unveiled that I152M-mutant TBX20 had decreased
function while Q195X-mutant TBX20 was effectively null. By PCR-sequencing, Qian et al. [57] screened TBX20 in 192 unrelated children with CHD, and discovered two mutations in four children, including p.H186D in two children (one child had an atrioventricular canal with secundum and primum atrial septal defects, as well as a cleft mitral valve with moderate mitral regurgitation, and the other child had patentology of Fallot) and p.L197P in other two children (one had patentology of Fallot and the other had atrial septal defect). However, the functional characteristics of the two mutations were not delineated. Liu et al. [58] made a sequence analysis of the exons 2 to 6 of TBX20 in 203 unrelated patients with CHD, and found three non-synonymous mutations of p.A63T, p.I121F and p.T262M in three patients with atrial septal defect, total anomalous pulmonary venous connection and TOF, respectively. However, functional effects of these sequence variants remain to be assayed. Posch et al. [59] analyzed the entire coding sequences of TBX20 in 170 unrelated patients with atrial septal defect, and found a novel mutation of p.I121M in a patient with positive family history of CHD. Genetic analysis of the index patient’s pedigree showed that the mutation co-segregated with CHD in the three-generation kindred. Functional assays showed that the mutation p.I121M resulted in a significantly increased transcriptional activity, which was further increased in the presence of transcription factors GATA4/5 and NKX2.5. By whole-exome sequencing, Liu and colleagues [60] analyzed a three-generation family with atrial septal defect, and identified a novel TBX20 mutation, p.D176N. However, functional analysis of the mutation was not performed. Pan and co-workers [30] sequenced the coding exons and flanking introns of the TBX20 gene in 146 unrelated patients with CHD, and identified a novel heterozygous TBX20 mutation, p.R143W in an index patient with double outlet right ventricle. Genetic analyses of the proband’s pedigree showed that the mutation co-segregated with the disease. Biological analysis revealed that mutant TBX20 had a significantly diminished transcriptional activity. By using the high resolution melting and DNA sequencing methods, Monroy-Muñoz and partners [31] made a search for TBX20 mutations in a group of 38 patients with atrial or ventricular septal defect, and found three missense mutations (p.Y309D, p.T370O, and p.M395R) in two patients with atrial septal defect, though functional characterization of these mutations were not carried out. In the present study, a novel TBX20 loss-of-function mutation was identified in patients with familial TOF alone or together with familial atrial septal defect, or sporadic persistent truncus arteriosus and ventricular septal defect. Taken collectively, these findings expand the phenotypic spectrum linked to TBX20 mutations and imply that genetically defective TBX20 is responsible for CHD in a subset of patients.

In conclusion, this study associates TBX20 loss-of-function mutation with increased vulnerability to TOF or persistent truncus arteriosus in humans for the first time, which provides novel insight into the molecular mechanism of CHD and suggests potential implications for genetic counseling and personalized treatment of the patients with CHD.

Acknowledgments

The authors thank the study subjects for their participation in this study. This work was supported by the grants from the National Natural Science Fund of China (81470372), the Key Program for Basic Research of Shanghai, China (14JC1405500) and the Major project of Shanghai Chest Hospital, China (grant no. 2014YZDH10102).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fonseca RA, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Munter P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey ZJ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.
2. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:2241–7.
3. Vecoli C, Pulignani S, Foffa I, Andreassi MG. Congenital heart disease: the crossroads of genetics, epigenetics and environment. Curr Genomics. 2014;15:390–9.
4. Kahr PC, Radke RM, Orswat S, Baumgartner H, Diller GP. Analysis of associations between congenital heart defect complexity and health-related quality of life using a meta-analytic strategy. Int J Cardiol. 2015;199:197–203.
5. Feltez G, Coronel CC, Pellanda IC, Lukáška J. Exercise capacity in children and adolescents with corrected congenital heart disease. Pediatr Cardiol. 2015;36:1075–82.
6. Rosenblum O, Katz U, Reuveny R, Williams CA, Dubnov-Raz G. Exercise performance in children and young adults after complete and incomplete repair of congenital heart disease. Pediatr Cardiol. 2015;36:1573–81.
7. Marelli A, Miller SP, Marino BS, Jefferson AL, Newburger JW. Brain in congenital heart disease across the lifespan: the cumulative burden of injury. Circulation. 2016;133:1951–62.
8. Jensen AS, Ildor L, Thomsen C, von der Hecke P, Mortensen J, Sørensen KE, Thilen U, Nagy E, Kofod KE, Ostrowski SR, Spanggaard L. Prevalence of cerebral and pulmonary thrombosis in patients with cyanotic congenital heart disease. Heart. 2015;101:1540–6.
9. Galaj N, Humbert M, Vachey JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Bøghetti M, Ghorbani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matsuca M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hooper M, Abovyan V, Vaz Carneiro A, Achenbach S, Agewall S, Almaneche C, Angiolillo D, Badano L, Albert Barberà J, Bouvaist H, Bueno H, Byrne RA, Carer J, Castro G, Erol K, Falk V, Funck-Brentano C, Gorenflo M, Granton J, Jung B, Kiely DG, Kirchhof P, Kjellstrom B, Landmesser U, Lekakis J, Lionis C, Lip GY, Orfanos SE, Park MH, Pierpola MF, Ponikowski P, Reveil MP, Rigas D, Rosenkranz S, Völker H, Luis Zamarano J. 2015 ESC/ERS Guidelines for the diagnosis and treatment

http://www.medsci.org
of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.

10. Lüscher TF. Frontiers in congenital heart disease: pulmonary hypertension, heart rhythm disorders, hypothyroidism. Eur Heart J. 2008;29:1477–89.

11. Buds W, Roos-Hessink J, Rijdde Hurst T, Eicken A, McDonagh TA, Lambriou E, Cespo-Leiro MG, Walker F, Frogoukdaki AA. Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2013;34:1419–27.

12. Stout KK, Bresbaby CS, Book WM, Cechin F, Chen JM, Dimopoulos K, Everett ML, Flaherty JT, Hsu HT, Kappas A, Law Y, Martin CM, Murphy AM, Ross HJ, Singh G, Spray TL. American Heart Association Council on Clinical Cardiology, Council on Functional Genomics and Translational Biology, and Council on Cardiovascular Radiology and Imaging. Chronic heart failure in congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2013;127:709–47.

13. McLeod CJ, Warren C. Recognition and management of arrhythmias in adult congenital heart disease. Curr Opin Cardiol. 2016;31:117–23.

14. Diller GP, Baumgartner H. Sudden cardiac death during exercise in patients with congenital heart disease: the exuberant paradox and the challenge of appropriate counseling. Eur Heart J. 2016;37:627–9.

15. Jortveit J, Eskandar L, Hirth A, Fomina T, Dohlen G, Hagemo P, Tell GS, Birkeand S, Øyen N, Holmstrøm H. Sudden unexpected death in children with congenital heart disease. Eur Heart J. 2017;38:626–32.

16. Williams RG. Late causes of death after congenital heart defects: a population-based study from Finland. J Am Coll Cardiol. 2016;68:499–501.

17. Fahed AC, Gelbl BD, Seidman JG, Seidman CE. Genetics of congenital heart disease: glass half empty. Circ Res. 2013;112:707–9.

18. Nilioudi D, Giannakoulias G, Parchanidou D, Panagiotidis T, Gatsoulis MA. Karvounis H. Adult congenital heart disease: a paradigm of epidemiological change. Int J Cardiol. 2016;218:269–74.

19. Khairy P, Ionescu-Biti R, Mackie AS, Abrahamowicz M, Pilotte L, Marelli AJ. Changing mortality in congenital heart disease. J Am Coll Cardiol. 2010;56:1149–57.

20. Patel SS, Burns TL. Non-genetic risk factors and congenital heart defects. Pediatr Cardiol. 2016;37:1343–55.

21. Andersen TA, Troelsen Kde L, Larsen LA. Of mice and men: molecular and developmental delay, and congenital heart defects. Am J Hum Genet. 2016;98:1235–42.

22. Laflaye S, Corseserier M, Basu M, Bowman JL, Fitzgerald-Sutt B, Zender G, Boske K, McBride KL, White P, Garg V. Utilisation of whole exome sequencing to identify causative mutations in familial congenital heart disease. Circ Cardiovasc Genet. 2016;9:320–9.

23. Priest RJ, Oseogawa K, Mohammed N, Nanda V, Kandu R, Schultz K, Lammer EJ, Girirajan S, Scheetz T, Waggott D, Reddy S, Bernstein D, Greenberg JS, Steimle JD, Yang MH, Moskovitz JP, Hurles M, Lifton RP, Nickerson D, Bansbich M, Eicher EE, Miltal S, Sheffield V, Quertermous T, Gelbl BD, Portman M, Ashley EA. De novo and rare variants at multiple loci support the oligogenic origins of atrioventricular septal heart defects. PLoS Genet. 2016;12:e1005963.

24. Werner P, Latney B, Beardon FR, Goldmuntz E. MESP1 mutations in patients with congenital heart defects. Hum Mutat. 2016;37:308–14.

25. Yoshida A, Moriyashi H, Nakaji M, Kitano M, Kim KS, Sagawa K, Ishikawa S, Satoh Y, Imadani K, Mitani Y, Kato H, Morita K, Ichikou S, Shibata H, Moriksi T. Genetic mutation analysis in Japanese patients with non-syndromic congenital heart disease. J Hum Genet. 2016;61:157–62.

26. Kelle AM, Bentley SJ, Roehena LG, Caballada AK, Olson TM. Eboxanatomy, left ventricular non-compaction, and early onset heart failure associated with a de novo a-tropomysin gene mutation. Am J Med Genet A. 2016;170:2186–90.

27. Cao Y, Wang J, Wei C, Hou Z, Li Y, Zhu H, Meng M, Wang W, Jing L. Genetic variations of NKX2.5 in sporadic atrial septal defect and ventricular septal defect in Chinese Yuanman population. Gene. 2016;575:29–34.

28. Yong YF. Mutations of NKX2.5 and GATA4 genes in the development of congenital heart disease. Gene. 2015;586:86–94.

29. Chen J, Qi B, Zhao J, Liu W, Duan R, Zhang M. A novel mutation of GATA4 (R122H) responsible for atrial septal defect. Genes. 2015;6:577–73.

30. Lu CX, Gong HR, Liu XY, Wang J, Zhao CM, Huang RT, Xue S, Yang YQ. A novel HAND2 loss-of-function mutation responsible for tetralogy of Fallot. Int J Mol Med. 2016;37:445–51.

31. Sun YM, Wang J, Yuan F, Xu Y, Li RG, Xu YJ, Qu XK, Shi HY, Hou XM, Huang RT, Xue S, Yang YQ. A HAND2 loss-of-function mutation causes familial ventricular septal defect and pulmonary stenosis. G3 (Bethesda). 2016;6:987–92.

32. Sun YM, Wang J, Xu XM, Xu Y, Li RG, Xu YJ, Huang RT, Xue S, Yang YQ. PITX2 loss-of-function mutation contributes to tetralogy of Fallot. Genet Med. 2017;19:557–68.

33. McCulley DJ, Black BL. Transcription factor pathways and congenital heart disease. Curr Top Dev Biol. 2012;100:253–77.

34. Gelbl BD, Chung WK. Complex genetics and the etiology of congenital heart disease. Cold Spring Harb Perspect Med. 2014;4:a013953.

35. Greulich F, Rudat C, Kispert A. Mechanisms of T-box gene function in the development of heart. Cardiovasc Res. 2011;91:212–22.

36. Neyses L, Greulich F, Rudat C, Kispert A. Mechanisms of T-box gene function in the development of heart. Cardiovasc Res. 2011;91:212–22.

37. Stennard FA, Elliott DE, Rankin S, Haast SJ, Lai D, McDonald LP, Jiang L, Leimena C, Preis JI, Dunwoodie SL, Elliott DE, Prall OW, Black BL, Satokata I, Mitani Y, Kato H, Shiraishi I, Morisaki T. T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development. 2005;132:2475–87.

38. Jabs DA, Satokata I, Mitani Y, Kato H, Shiraishi I, Morisaki T. T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development. 2005;132:2475–87.

39. Stennard FA, Elliott DE, Rankin S, Haast SJ, Lai D, McDonald LP, Jiang L, Leimena C, Preis JI, Dunwoodie SL, Elliott DE, Prall OW, Black BL, Satokata I, Mitani Y, Kato H, Shiraishi I, Morisaki T. T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development. 2005;132:2475–87.

40. Jabs DA, Satokata I, Mitani Y, Kato H, Shiraishi I, Morisaki T. T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development. 2005;132:2475–87.

41. Jabs DA, Satokata I, Mitani Y, Kato H, Shiraishi I, Morisaki T. T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development. 2005;132:2475–87.
55. Takeuchi JK, Mileikovskaia M, Koshiba-Takeuchi K, Heidt AB, Mori AD, Arruda EP, Gertsenstein M, Georges R, Davidson L, Mo R, Hui CC, Henkelman RM, Nemer M, Black BL, Nagy A, Bruneau BG. Tbx20 dose-dependently regulates transcription factor networks required for mouse heart and motorneuron development. Development. 2005;132:2463–474.

56. Kirk EP, Sunde M, Costa MW, Rankin SA, Wolstein O, Castro ML, Butler TL, Hyun C, Guo G, Ottway R, Mackay JP, Waddell LB, Cole AD, Hayward C, Keogh A, Macdonald P, Griffiths L, Fatkin D, Sholler GF, Zorn AM, Fereley MP, Winlaw DS, Harvey RP. Mutations in cardiac T-box factor gene TBX20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy. Am J Hum Genet. 2007;81:280–91.

57. Qian L, Mohapatra B, Akasaka T, Liu J, Ovorr K, Towbin JA, Bodmer R. Transcription factor neuromancer/TBX20 is required for cardiac function in Drosophila with implications for human heart disease. Proc Natl Acad Sci U S A. 2008;105:19833–8.

58. Liu C, Shen A, Li X, Jiao W, Zhang X, Li Z. T-box transcription factor TBX20 mutations in Chinese patients with congenital heart disease. Eur J Med Genet. 2008;51:580–7.

59. Posch MG, Gramlich M, Sunde M, Schmitt KR, Lee SH, Richter S, Kersten A, Perrot A, Panek AN, Al Khatib IH, Nemer C, Mégarbané A, Dietz R, Stiller B, Berger F, Harvey RP, Ozcelik C. A gain-of-function TBX20 mutation causes congenital atrial septal defects, patent foramen ovale and cardiac valve defects. J Med Genet. 2010;47:230–5.

60. Liu JJ, Fan LL, Chen JL, Tan ZP, Yang YF. A novel variant in TBX20 (p.D176N) identified by whole-exome sequencing in combination with a congenital heart disease related gene filter is associated with familial atrial septal defect. J Zhejiang Univ Sci B. 2014;15:830–7.